PURPOSE: To investigate long-term effects after intravitreal inhibition of vascular endothelial growth factor in nonproliferative macular telangiectasia type 2. METHODS: Nine patients with macular telangiectasia type 2 treated with 12 monthly intravitreal ranibizumab injections in 1 eye were investigated again after a mean follow-up of 6.0 ± 0.4 years. Functional assessment included best-corrected visual acuity and microperimetry testing. Morphologic investigations included optical coherence tomography imaging and fluorescein angiography. RESULTS: Mean visual acuity at baseline was similar in treated and control eyes (both 20/50; range: 20/32-20/125 in the treated eyes and 20/25-20/100 in the untreated eyes). None of the eyes had a neovascular membrane or a paracentral scotoma. At the last follow-up, more eyes of the treatment group had lost 2 or more lines on best-corrected visual acuity testing (4 vs. 1) and more eyes had developed an absolute paracentral scotoma (7 vs. 2). A secondary neovascular membrane had formed in four of the treated and in none of the untreated eyes. CONCLUSION: Vascular endothelial growth factor inhibition with monthly dosing over 1 year had no beneficial effect 5 years after cessation of therapy. The worse outcome in the treated eyes may be due to selection bias, small sample size, or a potential adverse effect of vascular endothelial growth factor inhibition in a degenerative, primarily nonvascular disease as macular telangiectasia type 2.
PURPOSE: To investigate long-term effects after intravitreal inhibition of vascular endothelial growth factor in nonproliferative macular telangiectasia type 2. METHODS: Nine patients with macular telangiectasia type 2 treated with 12 monthly intravitreal ranibizumab injections in 1 eye were investigated again after a mean follow-up of 6.0 ± 0.4 years. Functional assessment included best-corrected visual acuity and microperimetry testing. Morphologic investigations included optical coherence tomography imaging and fluorescein angiography. RESULTS: Mean visual acuity at baseline was similar in treated and control eyes (both 20/50; range: 20/32-20/125 in the treated eyes and 20/25-20/100 in the untreated eyes). None of the eyes had a neovascular membrane or a paracentral scotoma. At the last follow-up, more eyes of the treatment group had lost 2 or more lines on best-corrected visual acuity testing (4 vs. 1) and more eyes had developed an absolute paracentral scotoma (7 vs. 2). A secondary neovascular membrane had formed in four of the treated and in none of the untreated eyes. CONCLUSION:Vascular endothelial growth factor inhibition with monthly dosing over 1 year had no beneficial effect 5 years after cessation of therapy. The worse outcome in the treated eyes may be due to selection bias, small sample size, or a potential adverse effect of vascular endothelial growth factor inhibition in a degenerative, primarily nonvascular disease as macular telangiectasia type 2.
Authors: Daniel Pauleikhoff; Roberto Bonelli; Adam M Dubis; Frederic Gunnemann; Kai Rothaus; Peter Charbel Issa; Tjebo Fc Heeren; Tunde Peto; Traci E Clemons; Emily Y Chew; Alan C Bird; Ferenc B Sallo Journal: Acta Ophthalmol Date: 2019-04-09 Impact factor: 3.761
Authors: Tunde Peto; Tjebo F C Heeren; Traci E Clemons; Ferenc B Sallo; Irene Leung; Emily Y Chew; Alan C Bird Journal: Retina Date: 2018-01 Impact factor: 4.256
Authors: Tjebo F C Heeren; Diána Kitka; Daniela Florea; Traci E Clemons; Emily Y Chew; Alan C Bird; Daniel Pauleikhoff; Peter Charbel Issa; Frank G Holz; Tunde Peto Journal: Retina Date: 2018-01 Impact factor: 4.256
Authors: Kiran Chandra Kedarisetti; Raja Narayanan; Michael W Stewart; Nikitha Reddy Gurram; Arshad M Khanani Journal: Clin Ophthalmol Date: 2022-10-10
Authors: Katie M Litts; Mali Okada; Tjebo F C Heeren; Angelos Kalitzeos; Vincent Rocco; Rebecca R Mastey; Navjit Singh; Thomas Kane; Melissa Kasilian; Marcus Fruttiger; Michel Michaelides; Joseph Carroll; Catherine Egan Journal: Transl Vis Sci Technol Date: 2020-03-30 Impact factor: 3.048